胃癌：新型療法、未滿足的需求和TPP洞察報告，2026年

市場概覽

• 預計西班牙胃癌市場將從 2025 年的 2.2 億美元成長到 2035 年的 5.8 億美元。
• 這一成長得益於生物標記檢測的擴展和靶向癌症療法的引入。
• 正在研發的療法，包括與抗體藥物偶聯物 (ADC) 和免疫療法的聯合治療，有望加速市場擴張。

胃癌的新療法及對TPP的深入研究

Thelansis 的「胃癌：新型療法、未滿足的需求和目標產品概況 (TPP) 洞察報告，2026」對該適應症的關鍵新興療法和主要藥物開發機會進行了全面分析，包括新興的競爭格局、未滿足的需求、目標產品概況 (TPP)、臨床試驗設計以及關鍵意見領袖 (KOL) 的見解。

胃癌概述

胃癌是全球第五大常見惡性腫瘤，也是癌症死亡的第三大主要原因。它主要是一種起源於胃黏膜的腺癌，其主要致病因素包括幽門螺旋桿菌病菌感染、飲食致癌物質、吸菸、肥胖以及包括CDH1基因突變在內的遺傳症候群。分子分型包括EBV陽性、微衛星不穩定性高（MSI-H）、染色體不穩定和基因組穩定等亞型，每種亞型的治療意義各異。 HER2擴增見於約15-20%的胃癌和胃食道交界處腺癌，是重要的治療標靶生物標記。患者通常表現為上腹痛、吞嚥困難、早飽、體重減輕和貧血等症狀，由於發病緩慢，許多病例在確診時已晚期。切片檢查診斷需使用上消化道內視鏡切片確診，轉移性病灶及腹膜病灶則需以CT分期、PET顯像及腹腔鏡分期評估。在診斷時，全面的分子譜分析至關重要，包括HER2、MSI、PD-L1 CPS評分和FGFR2狀態。對於可切除的病變，手術全期FLOT化療是公認的標準治療方案。對於HER2陽性進行性胃癌，曲妥珠單抗合併化療是常用的治療方案，在DESTINY-Gastric試驗中，曲妥珠單抗德魯替康作為二線治療方案展現了突破性的療效。對於CPS評分≥5的HER2陰性進行性胃癌，Nivolumab單抗合併化療是公認的第一線治療方案。標靶CLDN18.2的佐貝妥昔單抗化療是CLDN18.2陽性腫瘤一線治療中一項新近核准的重要進展。對於微衛星不穩定性高（MSI-H）的腫瘤，Pembrolizumab免疫療法有效。晚期癌症的預後仍然較差，但為了實現以患者為中心的治療，整合多學科腫瘤委員會評估、營養支持和早期安寧療護至關重要。

主要亮點

• 在德國，根據存活率調整後，胃癌患者人數預計將從 2025 年的 120,844 人增加到 2035 年的 129,241 人。
• 由於胃癌通常在晚期才被診斷出來，因此仍然造成了極大的臨床負擔。
• HER2標靶療法和免疫療法對治療模式的影響越來越大。
• 在晚期和轉移性癌症的治療方面，仍存在巨大的未滿足需求。

透過對醫生和關鍵意見領袖 (KOL) 的調查所獲得的見解：

• 透過對關鍵意見領袖 (KOL) 的訪談，我們獲得了更深入的見解，從而進一步完善了調查結果。
• 調查問卷將根據客戶的要求進行客製化。

交付成果格式：

• PowerPoint簡報
• MS Excel

主要問題

• 詳細的競爭格局趨勢
• 管道分析
• 符合新興療法條件的患者
• 大公司
• 主要作用機制
• 發布日期預測等。
• 臨床試驗趨勢分析
• 目標患者群
• 試驗終點
• 測試設計
• 受試者招募標準等。
• 未滿足的需求和機遇
• 目前主要療法的有效性
• 未滿足需求的關鍵領域
• 主要未滿足需求的市場規模估算
• 目標產品概況
• 屬性和級別
• 醫生開立的處方
• 預期患者佔有率
• 關鍵意見領袖對領先新興療法的見解
• 意識
• 預期用途/處理線
• 對主要未滿足需求的滿意度
• KOL評論

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp &Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome &Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences（Nanjing）, Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

目錄

第1章：主要調查結果和分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章 競爭情勢

• 目前的治療方法
• 重點
• 診斷和治療過程/演算法
• 主要療法概述及關鍵意見領袖見解
• 新興療法
• 重點
• 診斷和治療過程/演算法
• 領先的新興療法—概述和關鍵意見領袖見解

第3章 產品屬性分析

• 重點
• 科學屬性
• 商業性屬性
• 產品定位

第4章：初步調查

• 目前治療狀態
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療環境
• 當前挑戰
• 未滿足的需求
• 新興療法
• 主要治療方法與目標患者族群的比較
• 主要特點和優勢
• 未來治療前景
• 未滿足的需求和關鍵意見領袖的期望

第5章：未滿足的需求和TPP分析

• 新興療法的主要未滿足需求和未來成就
• TPP分析與KOL預期

第6章 監理與報銷環境

第7章附錄

Gastric Cancer Emerging Therapy and TPP Insights

Thelansis's "Gastric Cancer Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Gastric Cancer Overview

Gastric cancer is the fifth most common malignancy and third leading cause of cancer mortality globally, arising predominantly as adenocarcinoma from the gastric mucosa, with Helicobacter pylori infection, dietary carcinogens, tobacco, obesity, and hereditary syndromes including CDH1 germline mutations constituting principal aetiological drivers. Molecular classification encompasses EBV-positive, microsatellite instability-high, chromosomally unstable, and genomically stable subtypes, each carrying distinct therapeutic implications. HER2 amplification occurs in approximately 15-20% of gastric and gastroesophageal junction adenocarcinomas, representing a critical actionable biomarker. Patients present with epigastric pain, dysphagia, early satiety, weight loss, and anaemia, with many diagnosed at advanced stages given insidious onset. Upper endoscopy with biopsy establishes histological diagnosis, while CT staging, PET imaging, and laparoscopic staging address metastatic and peritoneal disease assessment. Comprehensive molecular profiling encompassing HER2, MSI, PD-L1 CPS, and FGFR2 status is mandatory at diagnosis. Perioperative FLOT chemotherapy is the established standard for resectable disease. Advanced HER2-positive gastric cancer is addressed with trastuzumab combined with chemotherapy, with trastuzumab deruxtecan demonstrating transformative second-line efficacy in the DESTINY-Gastric trials. Nivolumab combined with chemotherapy is the established frontline standard for HER2-negative advanced disease with CPS of 5 or above. Zolbetuximab, targeting CLDN18.2, combined with chemotherapy represents a significant newly approved frontline advance for CLDN18.2-positive tumours. MSI-H disease benefits from pembrolizumab immunotherapy. Prognosis remains poor in advanced disease; multidisciplinary tumour board evaluation, nutritional support, and early palliative integration are indispensable to patient-centred care.

Key Highlights

• In Germany, survival-adjusted prevalent Gastric Cancer cases are projected to increase from 120,844 in 2025 to 129,241 by 2035.
• Gastric cancer continues to impose significant clinical burden due to late-stage diagnosis.
• HER2-targeted therapies and immunotherapies are increasingly influencing treatment paradigms.
• Unmet need remains high in advanced and metastatic disease management.

Market Overview

• The Spain Gastric Cancer market is projected to grow from USD 220 million in 2025 to USD 580 million by 2035.
• Growth is supported by expanding biomarker testing and adoption of targeted oncology therapies.
• Pipeline therapies including ADCs and immunotherapy combinations are expected to accelerate market expansion.

Insights driven by surveys with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• AstraZeneca
• Bristol-Myers Squibb
• Bold Therapeutics, Inc.
• RemeGen Co., Ltd.
• Ono Pharmaceutical Co., Ltd.
• Idience Co., Ltd.
• MacroGenics
• ImmVirx Pty Ltd
• Chimeric Therapeutics
• Qurgen Inc.
• Amgen
• Daiichi Sankyo
• AskGene Pharma, Inc.
• ALX Oncology Inc.
• Shanghai Henlius Biotech
• Merck Sharp & Dohme LLC
• Teclison Ltd.
• Iksuda Therapeutics Ltd.
• Cue Biopharma
• Genome & Company
• Hoffmann-La Roche
• Qurient Co., Ltd.
• MedPacto, Inc.
• ArriVent BioPharma, Inc.
• MOMA Therapeutics
• Aprea Therapeutics
• Genentech, Inc.
• Perspective Therapeutics
• HiFiBiO Therapeutics
• Qilu Pharmaceutical Co., Ltd.
• Monopar Therapeutics
• Sanofi
• Celldex Therapeutics
• SillaJen, Inc.
• Jazz Pharmaceuticals
• Incyte Corporation
• TransThera Sciences (Nanjing), Inc.
• Nurix Therapeutics, Inc.
• Poseida Therapeutics, Inc.
• Sutro Biopharma, Inc.
• Inhibrx Biosciences, Inc.
• BeiGene
• Arcus Biosciences, Inc.
• Apollomics Inc.

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)